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Biomarkers may facilitate detection of gastric cancer at an earlier stage and reduce mortality.
Here  we sought to determine if the glycosylation proﬁle of serum immunoglobulin G (IgG)
could distinguish patients with non-atrophic gastritis (NAG), duodenal ulcer (DU) and gastric
cancer (GC). Serum IgG was released and analyzed using nano-LC–TOF mass spectrometry.
Statistically signiﬁcant false discovery rate (FDR)-adjusted p-values were observed for 18
glycans, eight that differed signiﬁcantly between NAG and GC, three that distinguished NAG
from  DU, and eight that differed between DU and GC. The IgG glycosylation signature may
be  useful as a predictive marker for gastric cancer.
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1.  Introduction
Gastric cancer (GC) is the fourth most common malignancy,
but the second most common cause of cancer-related death
worldwide [1–3]. In the industrialized countries, the inci-
dence of gastric cancer has diminished dramatically over
the last 50 years, but in less developed countries in Eastern
Europe, Latin America and Asia, the disease remains a major
cause of morbidity and mortality [4]. Pathologically, there are
two histological types of gastric cancer: the diffuse- and the
intestinal-type (DGC and IGC, respectively) [5]. While DGC
is not well characterized, IGC is known to progress through
a series of histologic stages starting with gastritis and pro-
gressing over decades to atrophy (loss of glands), intestinal
metaplasia, dysplasia, and ﬁnally adenocarcinoma [6].
Helicobacter pylori is a bacterium that infects the gastric
epithelium of approximately 50% of the world’s population,
and is designated by the World Health Organization as a Type
I (deﬁnite) carcinogen. Individuals that are infected with H.
pylori nearly always develop a non-atrophic gastritis (NAG),
which in itself is largely asymptomatic, but in some cases pro-
gresses to gastric cancer. Alternatively, H. pylori infection may
also cause duodenal ulcer (DU), but these patients usually do
not develop gastric cancer [7], and so it is thought that these
individuals develop a host response to H. pylori infection that
is different from that in gastric cancer patients.
Mortality from gastric cancer is high because it produces
no known speciﬁc symptoms in its early stages when it is sur-
gically curable. If gastric cancer is detected at an early stage,
the 5-year survival is approximately 90% [8], but most cases
present with locally advanced or metastatic disease, which
has a median survival of only 24 months and a 5-year survival
of less than 15%. Therefore, early detection and preventa-
tive strategies are critical to decrease mortality from gastric
cancer [3]. The identiﬁcation of signature molecules for the
early detection of gastric cancer would thus be highly valuable.
One of the emerging ﬁelds for biomarker discovery is protein
glycosylation [9]. Several studies have identiﬁed altered gly-
cosylation patterns with varying health and disease states,
such as liver cirrhosis [10], rheumatoid arthritis [11], preg-
nancy [12] and aging (e.g. [13–15]), but also various types of
cancer (e.g. [16–20]), including gastric cancer [21]. This indi-
cates that protein glycosylation may reﬂect one’s balanced
physiological state, and is affected by most disease states.
The majority of glycomic studies performed to date have
focused on the global glycomic analysis of plasma or serum
[20], including our recent studies on gastric cancer [21]. These
approaches rely on the comprehensive release of glycans from
proteins, but ignore any protein correlation. It cannot be deter-
mined whether altered glycosylation proﬁles are due to altered
protein concentrations or to differential glycan expression.
Both site-speciﬁc and protein-speciﬁc glycosylation informa-
tion are lost. Protein-speciﬁc glycosylation analysis would
provide more  insight into the actual changes in glycosylation,
and would allow the establishment of hypotheses regarding
causes and effects of proteins with altered glycosylation.
Immunoglobulin G (IgG) is the most abundant glycoprotein in
plasma and serum. It is generally believed that glycans on IgG
contribute signiﬁcantly to the global serum glycome. c s 6 ( 2 0 1 5 ) 1–9
The large abundance of IgG and its role as a representative
protein of the immune system makes it an ideal protein to
examine the role of protein-speciﬁc glycosylation in cancer.
Several recent studies have focused on observing the rela-
tionship between health states and IgG glycosylation. Altered
glycosylation patterns of the Fc region of IgG have been
associated with several physiological states [22], including
autoimmune diseases [11,23,24], upon vaccination [25] and
with aging [26–28]. However, studies of IgG glycosylation in
cancer patients, and thus the role of the humoral immune
response in this disease, are scarce. Recently, studies deter-
mined altered IgG glycosylation patterns with ovarian [29,30]
and gastric [31] cancer. Clearly altered glycosylation patterns
were observed in both studies.
Mass spectrometry is often the method of choice for gly-
cosylation studies and our group recently introduced the use
of chip-based nano-liquid chromatography with time of ﬂight
mass spectrometry (nLC–chip-TOF-MS) on a porous graphitic
carbon stationary phase for the analysis of N-glycans [32,33].
This method has been shown to provide good separation, good
sensitivity and was shown to be highly stable [34]. In this
report, we analyzed the glycosylation pattern of IgG, taking
both Fab and Fc glycosylation into account, of a sample cohort
consisting of non-atrophic gastritis (NAG), duodenal ulcer
(DU), intestinal-type gastric cancer (IGC) and diffuse-type gas-
tric cancer (DGC) patients. Glycans that showed altered levels
with the different disease states were identiﬁed in this pilot
study.
2.  Materials  and  methods
2.1.  Sample  collection
2.1.1.  Patients
Human sera were obtained from the Gastroenterology Unit
of the Mexico General Hospital, Secretaria de Salud and the
Oncology Hospital, Instituto Mexicano del Seguro Social, both
in Mexico City, from October 1999 to July 2002. All patients
were at least 30 years old and presented for endoscopy
because of clinical indications. The protocol was approved
by the Research and Ethics Committees of each hospital and
informed consent letters were signed by all study participants.
2.1.2.  Clinical  and  histopathology  diagnosis
Gastric biopsies were obtained systematically from six deﬁned
locations in the gastric antrum, corpus, and transitional zone
and also from the location of a lesion, if one was identiﬁed
during endoscopy. Biopsies from each location were formalin
ﬁxed, parafﬁn embedded, and stained with hematoxylin and
eosin for histopathologic evaluation and classiﬁcation accord-
ing to the updated Sydney system by a single experienced
pathologist [35]. Final diagnosis was that of the most severe
histologic lesion or based on endoscopy ﬁndings in the cases
of duodenal ulcer.2.1.3.  Serology
A 5 mL  blood sample was drawn from each patient; serum was
obtained and frozen at −80 ◦C. Serum samples were tested by
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LISA for IgG antibodies against H. pylori whole cell antigens
s previously described [36].
.2.  Isolation  of  IgG  from  serum
mmunoglobulin G was captured from 5 L of serum using a
rotein G afﬁnity puriﬁcation step as previously published [37].
rieﬂy, 5 L of serum was added to 25 l Protein G coated beads
n 195 l Dulbecco’s phosphate buffered saline (DPBS) in a 96-
ell ﬁlter plate (Orochem, Lombard, IL). The IgG was allowed to
ind at room temperature for 1 h while shaking continuously,
fter which the ﬂow-through was collected using a vacuum
anifold. IgG bound to Protein G beads was washed four times
sing DPBS, followed by two times using micropuriﬁed water
o remove excess salt. IgG was eluted using 200 L of 100 mM
ormic acid in water and collected using a vacuum manifold.
he IgG fraction was dried under vacuum and subsequently
econstituted in 100 L of a 100 mM ammonium bicarbonate
olution with 5 mM DTT for N-glycan release.
.3.  N-glycan  release
-glycan release of IgG fractions was performed as described
reviously [38], with slight modiﬁcations. Brieﬂy, 50 L of the
aptured IgG fractions were denatured using six cycles alter-
ating between 100 ◦C and room temperature for 10 s each.
ne microliter of PNGaseF (New England Biolabs, Ipswich, MA)
as added to the samples, and enzymatic glycan release was
erformed overnight at 37 ◦C.
.3.1.  N-glycan  puriﬁcation  using  graphitized  carbon  SPE
ligosaccharides released by PNGaseF were puriﬁed using 96-
ell porous graphitic carbon (PGC) ﬁlter plates (40 L PGC,
lygen, Columbia, MD)  [16,33,39]. Brieﬂy, wells of the SPE
late were conditioned using 2 × 200 L of 80% acetonitrile
ACN) containing 0.05% triﬂuoroacetic acid (TFA), followed
y 2 × 200 L of water containing 0.05% TFA. Oligosaccharide
amples were diluted using 100 L of water and subsequently
oaded onto the wells. Wells were washed using 4 × 200 L of
ater and N-glycans were eluted using 2 × 200 L of 40% ACN
ontaining 0.05% TFA. All eluates were dried in vacuo prior to
nalysis.
.3.2.  nHPLC–chip-TOF-MS  analysis
-glycans were analyzed using an Agilent (Santa Clara,
A) 6200 series nanoHPLC–chip-TOF-MS, consisting of an
utosampler, which was maintained at 8 ◦C, a capillary loading
ump, a nanopump, HPLC–chip-MS interface and an Agi-
ent 6210 TOF mass spectrometer [34]. The microﬂuidic chip
glycan chip II, Agilent) contained a 9 mm × 0.075 mm i.d.
nrichment column coupled to a 43 mm × 0.075 mm i.d. ana-
ytical column, both packed with 5 m porous graphitized
arbon (PGC). N-glycans from IgG were reconstituted in 50 L
f water and 1 L of sample was used for injection. Upon
njection, the sample was loaded onto the enrichment col-
mn  using 3% ACN containing 0.1% formic acid (FA, Fluka,
t. Louis, MO). After the analytical column was switched in-
ine, the nano-pump delivered a gradient of 3%ACN with 0.1%
A (solvent A) and 90% ACN with 0.1% FA (solvent B). The s 6 ( 2 0 1 5 ) 1–9 3
mass spectrometer was operated in the positive mode, and
ions were scanned over a mass range from m/z  400 to 3000.
2.4.  Data  processing
Data analysis was performed using Masshunter® qualitative
analysis (version B.03.01, Agilent) and Microsoft® Excel® for
Mac 2011 (version 14.1.3, Microsoft) [34]. Data was loaded into
Masshunter qualitative analysis, and glycan features were
identiﬁed and integrated using the Molecular Feature Extrac-
tor algorithm. First, signals above a signal to noise threshold of
5.0 were considered. Then, signals were deconvoluted using a
tolerance of 0.0025 m/z ± 10 ppm. The resulting deconvoluted
masses were subsequently annotated using a retrosynthetic
theoretical glycan library [40], where a 15 ppm mass error was
allowed. Glycan compositions and volume were exported to
csv-format for further evaluation.
2.5.  Statistics
Missing values for individual glycan compositions were ﬁlled
in on the log scale by using a weighted k-nearest neighbor
algorithm [41]. The values for the composition groups (high
mannose, etc.) were computed by adding together the appro-
priate compositions on the raw scale, then converting back to
the log scale. The subjects were randomly split into 6 groups,
as balanced as possible with respect to diagnosis and age
group (30–39, 40–49, 50–59, 60+). In all six groups combined,
then with each of the groups successively left out, glycan com-
positions were tested for signiﬁcance using a 3-way analysis
of variance (ANOVA) with sex, age group, and diagnosis class
as the explanatory variables and the logarithmic compositions
as responses. To account for multiple testing, the method of
Benjamini and Hochberg [42] was applied to control the false
discovery rate (FDR) at 10%. A glycan was declared signiﬁcantly
different among the three diagnosis groups if the FDR adjusted
p-value of the F-test for inclusion of diagnosis in the model was
less than 0.1. Once diagnosis was declared statistically signif-
icant, differences among the diagnosis classes were identiﬁed
by the Tukey–Kramer method [43].
3.  Results
3.1.  Subject  characteristics
A cohort of serum samples from 66 individuals with NAG
(n = 18), DU (n = 17), IGC (n = 15) and DGC (n = 16) was selected.
H. pylori infection is known to nearly always cause gastritis
[7]. Because the prevalence of H. pylori infection is very high
in Mexico and other Latin American countries [44], and virtu-
ally all H. pylori-infected individuals develop gastritis, the NAG
group serves as the most appropriate control. Like the other
groups, they are infected with H. pylori,  but do not develop
clinical disease. The seroprevalence of H. pylori was 77% in
the cohort studied here (Table 1). Individuals that develop DU
are highly unlikely to develop GC, and may therefore create
a physiological environment that is protective of GC. There-
fore, a group of individuals with DU was included in the study
cohort. The groups of NAG and DU were matched for age and
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Table 1 – Patient demographics and clinical proﬁles.
Diagnosis N Mean age (range) Sex H. pylori (+)
M F
Non-atrophic gastritis 18 46.1 (30–68) 10 8 15
Duodenal ulcer 17 53.2 (31–80) 8 9 15
Gastric cancer
6) 
1) Intestinal 15 69.3 (48–8
Diffuse 16 57.5 (36–8
Total 66
sex. Age- and sex-matched samples were not available for the
GC group since these patients are predominantly older and of
male sex.
4.  Glycans  detected  on  IgG
To evaluate the N-glycan proﬁles originating from
immunoglobulin G (IgG, for a schematic overview see
Supplementary Fig. S1) as a possible biomarker for gastric
cancer, IgG was immunopuriﬁed from the serum samples.
The purity of the obtained IgG fractions was assessed by
SDS-PAGE (Supplementary Fig. S2) and mass spectrometry. In
a tryptic digest of the captured fraction, IgG heavy and light
chains were identiﬁed with high conﬁdence. Low levels of
albumin were also observed, but human albumin is not gly-
cosylated and does therefore not interfere with the analysis.
These results indicate that highly pure IgG fractions were
obtained and that the observed glycans are from IgG.
Previous mass spectrometry based studies of IgG glycosyl-
ation patterns in disease states have been performed using
tryptic IgG glycopeptides, which do not readily allow identiﬁ-
cation of glycans on the variable region of IgG. To get a more
complete overview of the IgG glycosylation pattern and its
associations with gastric cancer, N-glycans were released from
the intact protein. A typical chromatogram obtained from IgG
glycans is depicted in Fig. S3 in the supplementary informa-
tion. A total of 48 glycan compositions from IgG could be
observed consistently (>70% of the samples) throughout the
sample set, and they are listed in Table S4 in the supple-
mentary information. Several glycan species, particularly high
mannose- (#27, 28, 35, 36, 38 and 48 in Table S4) and hybrid-
(#39, 40, 42, 44 and 47 in Table S4) type glycans, have not been
found on IgG in previous studies, and are therefore, most likely
linked to the Fab portion of the antibody.
This is, to our knowledge, the ﬁrst report of the total IgG gly-
cosylation proﬁle in human serum, and this study thus allows
the determination of the abundance and variability of the indi-
vidual glycan compositions on IgG. The glycan compositions
were ordered according to their average relative abundance
in the samples in supplementary Table S4. To evaluate the
inter-individual variation in IgG glycosylation, the standard
deviation was calculated (Table S4). A relative S.D. of approxi-
mately 25% was observed for the higher abundant glycans and
a relative S.D. of approximately 50% was observed for lower
abundant glycans. The total plasma glycosylation pattern is
highly variable with an average relative S.D. of 24% [45], and the
results presented here show that the variation in glycosylation
on IgG is similar to the overall plasma proﬁle. The increased12 3 7
11 5 14
S.D. observed for lower abundant glycans in this study is most
likely a reﬂection of the analytical variation, which is relatively
larger for lower abundant glycans.
5.  IgG  glycans  as  candidate  markers  for  the
detection  of  gastric  cancer
To evaluate whether IgG glycans can be used to segregate
cases of gastric cancer, we ﬁrst conducted ANOVA analysis
on the glycans grouped according to their structural features:
high mannose, truncated, hybrid, biantennary, triantennary,
bisected, fucosylated and sialylated glycans. No signiﬁcant
differences were observed between, IGC and DGC  (data not
shown). Therefore, the two cancer groups were merged into
a single GC group, and ANOVA was performed with diagnosis
classes NAG, DU and GC. Signiﬁcant differences were observed
among the diagnostic groups for the truncated, biantennary
and sialylated glycan groups, with FDR-adjusted p-values of
0.021, 0.017 and 0.039, respectively (Fig. 1). Further evaluation
using a Tukey test indicated that signiﬁcantly increased levels
of truncated glycans were observed in the GC group compared
to the NAG group, while levels of biantennary glycans were
decreased in GC compared to NAG. Sialylated glycans were sig-
niﬁcantly decreased between the DU group and the GC group
(Table 2). No signiﬁcant differences were observed between H.
pylori positive and H. pylori negative individuals. These results
indicate a different IgG glycosylation proﬁle between the dif-
ferent disease groups and justiﬁed further analysis on single
glycans.
Three-way ANOVAs were performed on individual glycan
compositions. Statistically signiﬁcant FDR-adjusted p-values
were observed for 18 glycans. A Tukey test was performed to
further evaluate the signiﬁcant glycans and the results are
depicted in Table 2. There were eight glycans that differed
signiﬁcantly between GC and both NAG and DU, while three
differed signiﬁcantly between NAG and DU (Fig. 2). Of the eight
glycans that differed between NAG and GC, levels of ﬁve non-
galactosylated structures (H3N4F1, H3N5, H3N5F1, H5N3 and
H4N5F1S1, where H = number of hexoses, N = hexosamines,
F = fucoses, and S = NeuAc sialic acids) were increased in GC,
while levels of three fully galactosylated glycans (H5N4F1S1,
H5N4F1S2 and H5N5F1) were decreased, indicating a loss of
galactoses on the IgG of GC patients. These results are illus-
trated in Fig. 3. Interestingly, one of the signiﬁcant glycans is a
hybrid type glycan that is likely located on the Fab part of IgG
as its presence has not been reported using glycopeptide anal-
ysis. Further direct analysis is needed to conﬁrm the location
of the individual glycans.
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Table 2 – Tukey test p-values and differences for glycans declared signiﬁcant by FDR-adjusted p-value. Glycans with signiﬁcant differences are shown in bold.
Composition GC vs NAG DU vs NAG GC vs DU
Difference Lower 95%
CI
Upper 95%
CI
FDR
adjusted
p-value
Difference Lower 95%
CI
Upper 95%
CI
FDR
adjusted
p-value
Difference Lower 95%
CI
Upper 95%
CI
FDR
adjusted
p-value
Truncated 14.8% 3.3% 27.6% 0.0074 3.1% −8.6% 16.4% 0.8120 11.3% −0.1% 24.0% 0.0514
Biantennary −13.7% −21.7% −4.8% 0.0019 −6.4% −16.3% 4.7% 0.3357 −7.7% −16.5% 2.0% 0.1369
Sialylated −7.8% −15.4% 0.5% 0.0703 1.4% −8.1% 11.8% 0.9411 −9.0% −16.7% −0.7% 0.0322
H3N3F1 29.3% −0.9% 68.7% 0.0603 26.0% −7.0% 70.6% 0.1689 2.6% −21.7% 34.5% 0.9709
H3N4F1 36.7% 14.4% 63.3% 0.0002 13.4% −7.4% 38.9% 0.3040 20.5% 0.6% 44.5% 0.0416
H3N5 31.2% 0.0% 72.0% 0.0495 28.5% −5.7% 75.0% 0.1343 2.1% −22.5% 34.5% 0.9820
H3N5F1 31.9% 1.8% 70.9% 0.0337 12.7% −16.1% 51.5% 0.5964 17.0% −10.1% 52.4% 0.3317
H4N3F1 −2.9% −32.1% 38.9% 0.9787 −39.8% −60.0% −9.4% 0.0114 61.2% 11.9% 132.1% 0.0072
H4N4F1 3.1% −11.7% 20.3% 0.8854 −14.9% −28.6% 1.6% 0.0808 21.1% 3.4% 41.7% 0.0136
H4N5S1 51.8% −2.4% 136.2% 0.0680 119.8% 32.7% 264.1% 0.0012 −30.9% −56.0% 8.4% 0.1273
H4N5F1S1 46.3% 4.9% 104.0% 0.0212 57.0% 7.4% 129.5% 0.0160 −6.8% −33.6% 30.8% 0.8714
H5N3 156.0% 8.4% 504.8% 0.0289 17.7% −55.9% 214.0% 0.9157 117.4% −9.4% 421.9% 0.0918
H5N4 −20.0% −37.6% 2.6% 0.0870 −0.2% −24.8% 32.5% 0.9999 −19.8% −37.7% 3.2% 0.0976
H5N4F1 −23.8% −42.4% 0.8% 0.0582 −24.7% −45.2% 3.7% 0.0917 1.1% −23.9% 34.4% 0.9951
H5N4F1S1 −16.8% −29.9% −1.2% 0.0333 −12.2% −27.8% 6.9% 0.2573 −5.3% −20.5% 12.9% 0.7387
H5N4F1S2 −24.5% −42.3% −1.1% 0.0392 −5.6% −30.5% 28.4% 0.8952 −20.0% −39.2% 5.2% 0.1317
H5N5 −21.1% −43.7% 10.5% 0.2164 11.3% −24.3% 63.6% 0.7831 −29.1% −49.8% −0.1% 0.0493
H5N5S1 −29.8% −52.2% 2.9% 0.0752 13.1% −26.9% 75.2% 0.7763 −38.0% −58.0% −8.4% 0.0126
H5N5F1 −34.9% −55.1% −5.5% 0.0202 −3.9% −37.1% 47.0% 0.9730 −32.3% −53.6% −1.0% 0.0429
H6N5S3 −23.2% −54.1% 28.3% 0.4360 59.7% −11.2% 187.2% 0.1421 −52.0% −71.5% −18.9% 0.0038
H6N5F1S2 −14.3% −40.5% 23.4% 0.5689 47.4% −2.7% 123.4% 0.0722 −41.8% −59.9% −15.7% 0.0024
6  e u p a o p e n p r o t e o m i c s 6 ( 2 0 1 5 ) 1–9
Fig. 1 – Glycan groups show altered abundances with gastric cancer. Bars represent the mean (±SEM) relative abundance of
the glycan features in each group. Glycan features for a given group do not sum to 100% because there are glycans that have
more than a single feature. For example, if a glycan is fucosylated and sialyated, it is counted is both subgroups. Signiﬁcant
differences (denoted by *) were  found among the diagnostic groups for truncated, biantennary, and sialyated glycans with
y.FDR-adjusted p-values of 0.021, 0.017 and 0.039, respectivel
While the direction of the change was usually similar for
both DU and GC relative to NAG, eight glycan compositions
altered signiﬁcantly between DU and GC, of which six were
not signiﬁcant between NAG and GC. Here non- and mono-
galactosylated glycans containing a fucose (H3N4F1, H4N3F1
and H4N4F1) were increased in GC, while fully galactosylated
glycans with a bisecting GlcNAc and triantennary sialylated
glycans were decreased (H5N5, H5N5S1, H5N5F1, H6N5S3 and
H6N5F1S2, see Fig. 2B). These ﬁndings hold a promise for a
predictive marker for gastric cancer, which may be able to
distinguish between the non-malignant DU condition and GC.
6.  Discussion
Protein-speciﬁc glycan biomarkers represent a new paradigm
for the diagnosis of cancer. The research presented here
provides results regarding the differentiating potential of IgG-
glycosylation signatures for the detection of gastric cancer
from human blood. In this pilot study it was observed that lev-
els of several truncated glycans, where the galactose is missing
on at least one arm, are increased with gastric cancer, while
levels of several fully galactosylated bi- and tri-antennary
structures were decreased (Table 2). We recently reported the
association of increased levels of non-galactosylated bianten-
nary glycans with gastric cancer in total serum in the same
cohort [21]. The results reported here differ in that we  have
now identiﬁed glycan proﬁles speciﬁcally on IgG that are asso-
ciated with gastric cancer. Similar results were also obtained
in a previous study [31], which focused only on the analysis of
the IgG Fc glycosylation site. Together these results strongly
suggest that the altered levels of non-galactosylated bianten-
nary glycans observed in serum is mostly caused by the altered
IgG glycosylation signature.Further validation studies in additional sample cohorts will
be needed to evaluate whether the glycosylation pattern of
IgG has sufﬁcient predictive power and could indeed serve
as a biological marker for GC, whether alone or in combina-
tion with other proteins and glycans [46]. It has to be noted
that the current studies have focused on detection in indi-
viduals that have already developed GC. Such markers would
be a tremendous improvement over current diagnostics, but
the development of markers for individuals with precancerous
lesions, e.g. atrophy, metaplasia and dysplasia would be even
more  beneﬁcial. Further studies should, therefore, include
specimens from these disease classes.
The structure of the IgG molecule is signiﬁcantly affected
by the glycans that are attached to it, and therefore the gly-
cans play an important role in the afﬁnity of the Fc region
of the protein for the Fc receptors. Unglycosylated antibod-
ies are severely impacted in their afﬁnity for the Fc receptors
and have much lower activities [47], which is likely due to a
change in conformation of the IgG molecule. The removal of
just the galactose residues off the IgG glycans, as observed in
patients with gastric cancer, has also been shown to decrease
the activity of antibodies, though to a much lesser extent [48].
Therefore, our ﬁndings indicate that the immune response is
likely altered in gastric cancer patients.
It is now known that chronic inﬂammation is one of the
characteristics of cancer [49], and multiple studies indicate
that several of the carcinogens not only initiate the devel-
opment of cancerous cells, but also trigger activation of the
immune system that over time leads to chronic inﬂammation
and provides the right tumor environment [50]. This effect is
also true for H. pylori-induced GC, where the bacterial infec-
tion ﬁrst causes inﬂammation prior to the development of
precancerous lesions and later cancer [6]. It is currently not
known whether the inﬂammatory process mostly plays an
important role in the development of cancer, or whether the
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Fig. 2 – Levels of Individual glycans differ with disease
state. Mean difference as well as 95% conﬁdence interval is
displayed for glycans that differ signiﬁcantly between (A)
NAG versus DU (black) and NAG versus GC (gray), and (B) DU
versus GC. Levels of glycans are signiﬁcantly altered when
the 95% C.I. does not include 0. Positive values indicate
increased levels, while negative values indicate decreased
levels of a certain glycan. X-axis labels represent the glycan
composition (reading left to right): number of hexoses,
N-acetylhexosamines, fucoses, and sialic acids. For
example 3 4 1 0 indicates 3 hexoses, 4
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Fig. 3 – The altered IgG glycosylation proﬁle that is
associated with gastric cancer. Increasing glycans are
shown on the left, while decreasing glycans are shown on
the right. Symbol key: blue square: N-acetyl glucosamine,
green circle: mannose, yellow circle: galactose, red triangle:
fucose and purple diamond: sialic acid.-acetylhexosamines, 1 fucose, and 0 sialic acids.
ancer induces an inﬂammatory response, or both. Altered
gG glycosylation proﬁles have been described in autoimmune
nd inﬂammatory diseases [11,23,51,52]. Thus, altered IgG
lycosylation proﬁles in gastric cancer may reﬂect the inﬂam-
atory process. However, since the control group in this study
onsisted of NAG, which is a chronic (albeit asymptomatic)
nﬂammatory condition, it is more  likely that the altered gly-
osylation proﬁle is induced by the cancer. Further research
oward the regulation of the altered glycosylation patterns on
gG as well as the speciﬁc effects on IgG functionality would
rovide more  insight into the immune response that is asso-
iated with cancer in general and more  speciﬁcally gastric
ancer.
Overall, this study shows the human serum IgG gly-
osylation signature in gastric cancer, duodenal ulcer and
on-atrophic gastritis patients. Eight glycans were expressed
t altered levels between GC and NAG: truncated glycanswere increased with gastric cancer, while fully galactosylated
biantennary structures were decreased. When an individual
develops DU they are highly unlikely to develop GC and it is
speculated that a physiological environment is created that
is protective of GC. Interestingly, when comparing DU to GC,
similar glycans were signiﬁcantly increased, while galacto-
sylated glycans with a bisecting GlcNAc and triantennary
sialylated glycans were decreased, indicating indeed a dif-
ferent response between DU and GC. The IgG glycosylation
signatures that are presented here may provide predictive
power for the detection of GC. Further studies are needed to
determine their predictive potential as well as their biological
background.
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